13 October 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in iCMR-guided cardiac ablation products, is pleased to announce that the Semmelweis University Heart and Vascular Centre in Budapest Hungary, has signed a purchase agreement with Imricor, making it the eleventh site to establish an iCMR lab to perform ablations with Imricor’s products.

30 August 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Sales Distribution Agreement with NordicNeuroLab AS, a leading maker of MRI compatible in-room monitors, headquartered in Norway.

lobal leader in MRI-guided cardiac ablation products, has achieved an important milestone in its geographic expansion plans with the Company’s Advantage-MR EP Recorder/Stimulator system receiving Australian TGA approval.

2 April 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Distribution Agreement with Australian-owned medical distribution company Regional Health Care Group Pty Ltd (RGCH), based in Sydney.

8 March 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Helios Leipzig Heart Centre in Germany has commenced procedures.

24 February 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Maastricht University Medical Centre+ (MUMC+) in the Netherlands has commenced procedures since the extended lockdowns across Europe precluded elective surgeries. The team at MUMC+ successfully performed two atrial flutter ablations yesterday.

29 December 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided ablation products Imricor is pleased to announce that to support the Company’s future growth strategy, Mr Gregg Stenzel has been appointed to the role of Chief Operating Officer, effective 1 January 2021. In this newly established role, Mr Stenzel will lead the execution of Imricor’s strategic plan across most functional areas of the business, providing greater capacity for CEO, Steve Wedan, to drive the establishment of new clinical sites as the business accelerates the commercial roll-out of its products across Europe in 2021.

10 December 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce they have entered into a Supply and Sales Agreement with Osypka AG Medizintechnik (Osypka), a German producer of radiofrequency ablation generators.

24 November 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the University Hospital in Münster (UKM), Germany has signed a purchase agreement with Imricor, marking the ninth site the Company has contracted this year.

Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in iCMR guided cardiac ablation products, is pleased to announce the Schleswig-Holstein University Medical Centre (Universitätsklinikum Schleswig-Holstein, or UKSH), in Lübeck Germany, has signed a purchase agreement with Imricor. The Company is working with the Lübeck University Heart Centre, which is under the umbrella of UKSH, to schedule installation, training, and first procedures.